{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-26-000036","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2026-07-30T20:08:09+00:00","discovered_at":"2026-07-30T20:09:00.242764+00:00","generated_at":"2026-07-30T20:09:13.758458+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Guardant Health Q2 revenue up 44% to $335M; raises 2026 guidance to $1.34-1.36B","bullets":["Q2 revenue $335.0M (+44% YoY); Oncology $219.1M (+38%), Screening $52.9M (+258%).","Net loss $120.1M ($0.90/share); non-GAAP net loss $56.2M ($0.42/share).","2026 revenue guidance raised to $1.34-1.36B (prior $1.30-1.32B), growth 36-38%.","Screening revenue guidance raised to $218-230M; Shield volume 270k-285k tests.","FDA approved Guardant360 Liquid CDx; Shield included in ACS guidelines, UnitedHealth coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-26-000036","json":"https://secwatch.observer/filing/0001576280-26-000036.json","markdown":"https://secwatch.observer/filing/0001576280-26-000036.md","text":"https://secwatch.observer/filing/0001576280-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628026000036/0001576280-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628026000036/gh-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:09:13.758458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}